Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Eli lilly and company symbols : Alny save search
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL M | $231.37 -2.21% -2.27% 250K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $7.55 -5.51% -5.69% 3.2M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $9.49 -3.36% -3.48% 480K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL M | $231.37 -2.21% -2.27% 250K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $5.355 -7.83% -10.46% 60K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.91 -1.51% -1.53% 170K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $21.72 -2.07% -1.98% 760K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
Published: 2023-06-13 (Crawled : 11:00) - investor.alkermes.com
ENDPQ 6 d | $0.0018 500.0% -50.0% 360K
|
n/a
|
| O: -47.17%
H: 110.71%
C: 96.43%
IRM | $74.84 -1.55% 0.21% 1.2M
|
Finance
|
| O: -0.18%
H: 0.94%
C: 0.2%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.37%
H: 0.84%
C: 0.46%
AMRX | $5.54 0.36% 0.54% 1.1M
|
Health Technology
|
| O: 0.4%
H: 8.7%
C: 1.98%
ZLAB | $14.2 -0.77% -0.88% 640K
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: -0.93%
VRTX | $397.36 0.2% 0.23% 1.1M
|
Health Technology
|
| O: 0.08%
H: 1.04%
C: 0.36%
UTHR | $235.08 1.07% 1.12% 330K
|
Health Technology
|
| O: -0.65%
H: 2.13%
C: 1.37%
RARE | $42.87 -8.79% -9.63% 1.7M
|
Health Technology
|
| O: 0.72%
H: 2.22%
C: 0.5%
SRPT | $118.31 -3.71% -3.79% 860K
|
Health Technology
|
| O: 0.55%
H: 2.23%
C: -0.71%
SAGE | $15.32 -0.78% -0.72% 850K
|
Health Technology
|
| O: 0.07%
H: 2.89%
C: 1.85%
PTCT | $25.68 -2.8% -2.8% 960K
|
Health Technology
|
| O: -0.3%
H: 2.48%
C: 1.97%
PRTA 4 | $21.99 -1.12% -1.14% 530K
|
Health Technology
|
| O: 0.29%
H: 5.34%
C: 4.38%
NBIX | $131.74 -2.17% -2.26% 770K
|
Health Technology
|
| O: 0.05%
H: 2.35%
C: 2.29%
MDXG F | $6.35 -1.4% -1.26% 500K
|
Health Technology
|
| O: 0.85%
H: 1.34%
C: -0.17%
LPTX | $3.0 -7.41% -8.0% 520K
|
Health Technology
|
| O: 0.0%
H: 9.63%
C: 9.63%
JAZZ | $110.91 0.3% 0.29% 600K
|
Health Technology
|
| O: -0.02%
H: 1.93%
C: 1.16%
IRWD | $7.79 -1.14% -1.09% 2.9M
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -3.42%
IONS | $41.55 -0.46% -0.43% 590K
|
Health Technology
|
| O: 0.17%
H: 1.25%
C: 0.46%
INFI | $0.016 12.5% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.76%
INCY | $53.43 -0.78% -0.8% 1.6M
|
Health Technology
|
| O: -0.48%
H: 1.44%
C: 0.24%
IDXX | $491.29 -1.31% -1.23% 350K
|
Health Technology
|
| O: 0.31%
H: 1.9%
C: 1.42%
EXEL 4 | $22.7 -0.48% -0.51% 1.8M
|
Health Technology
|
| O: 0.05%
H: 0.89%
C: 0.52%
CYCN | $3.32 -1.48% 12.62% 2.4K
|
Health Technology
|
| O: 6.44%
H: 0.41%
C: -1.94%
BPMC | $85.18 -2.37% -2.42% 510K
|
Health Technology
|
| O: 0.62%
H: 2.47%
C: 0.53%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -1.06%
H: 6.94%
C: -2.15%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.07%
H: 2.64%
C: 2.23%
ALKS | $24.02 -1.64% -1.75% 2.7M
|
Health Technology
|
| O: 0.19%
H: 1.58%
C: 0.64%
ACAD M | $16.89 -1.46% -1.48% 1.1M
|
Health Technology
|
| O: 0.12%
H: 1.83%
C: 1.58%
IBIO | $1.93 -4.46% 0.0% 210K
|
Health Technology
|
| O: 16.68%
H: 3.53%
C: -11.59%
Nonalcoholic Steatohepatitis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain - Madrigal, Intercept, AstraZeneca, Gilead, Pfizer, Alnylam, Eli Lilly and Company, Novo Nordisk
Published: 2023-04-24 (Crawled : 15:00) - prnewswire.com
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -1.02%
H: 0.31%
C: -0.24%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: -0.49%
VKTX | $66.95 -2.43% -2.48% 2M
|
Health Technology
|
| O: 0.99%
H: 2.87%
C: -0.42%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: 0.0%
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 0.63%
H: 1.35%
C: 0.45%
MDGL M | $231.37 -2.21% -2.27% 250K
|
Health Technology
|
| O: -0.33%
H: 1.28%
C: 1.12%
LPCN | $5.355 -7.83% -10.46% 60K
|
Health Technology
|
| O: -2.31%
H: 7.94%
C: 1.01%
IONS | $41.55 -0.46% -0.43% 590K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -3.64%
HEPA | $2.18 -0.46% -2.1% 9.9K
|
Health Technology
|
| O: 0.04%
H: 1.48%
C: -3.31%
GALT | $3.91 -1.51% -1.53% 170K
|
Health Technology
|
| O: 0.0%
H: 1.04%
C: -4.17%
CWBR | $0.761 -11.88% 590K
|
Health Technology
|
| O: -3.68%
H: 1.1%
C: -1.63%
ALT | $7.55 -5.51% -5.69% 3.2M
|
Commercial Services
|
| O: -0.69%
H: 0.87%
C: -4.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -0.08%
H: 0.18%
C: -2.07%
ETNB | $9.49 -3.36% -3.48% 480K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -5.88%
companies active rapid market
DelveInsight Evaluates a Robust RNA Interference Pipeline as Key 85+ Pharma Companies Set Foot in the RNA Interference Space
Published: 2022-11-01 (Crawled : 16:00) - prnewswire.com
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 7.74%
H: 0.17%
C: 0.17%
JNJ | $147.59 0.05% -0.18% 6.4M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -4.49%
H: 3.81%
C: 1.95%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
MRNA S | $103.86 -1.22% -1.23% 1.9M
|
Health Technology
|
| O: 2.95%
H: 2.66%
C: -0.1%
CVAC | $2.65 -8.94% -9.81% 930K
|
Health Technology
|
| O: 1.1%
H: 3.4%
C: -1.36%
BNTX | $87.89 1.63% 1.59% 710K
|
Health Technology
|
| O: 4.54%
H: 4.25%
C: 0.13%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 1.06%
H: 2.53%
C: 1.75%
space pharma companies set
Novo Nordisk to Acquire Dicerna
Published: 2021-11-18 (Crawled : 13:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 0.51%
H: 0.37%
C: -0.2%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 2.14%
H: 0.69%
C: -0.26%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 5.69%
H: 4.06%
C: -1.82%
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
preclinical collaboration research license pre-clinical
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
Published: 2021-11-09 (Crawled : 13:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -1.59%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.44%
H: 0.0%
C: -2.69%
financial results results
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
Published: 2021-11-04 (Crawled : 18:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 0.06%
H: 0.26%
C: 0.19%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -0.24%
H: 7.69%
C: 7.59%
kidney
Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
Published: 2021-10-19 (Crawled : 12:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.08%
H: 1.66%
C: 1.26%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.03%
H: 1.46%
C: 1.36%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -0.16%
H: 1.75%
C: 1.48%
results
Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
Published: 2021-10-15 (Crawled : 21:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 0.78%
H: 1.5%
C: 1.11%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.39%
H: 0.0%
C: 0.0%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.34%
H: 0.09%
C: -0.69%
kidney
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: -1.28%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -7.01%
H: 2.22%
C: -1.77%
alcohol use disorder treatment phase 1 trial
Dicerna Announces New Executive Leadership Appointments
Published: 2021-09-22 (Crawled : 12:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.82%
H: 0.74%
C: -0.07%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.07%
H: 0.45%
C: -0.74%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.58%
H: 0.11%
C: -1.62%
AKBA | $1.39 -4.8% -4.29% 3.6M
|
Health Technology
|
| O: -1.05%
H: 2.48%
C: -0.35%
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
Published: 2021-08-09 (Crawled : 12:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 1.64%
H: 0.89%
C: 0.58%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.33%
H: 3.2%
C: 0.98%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.37%
H: 4.18%
C: 3.46%
financial results results
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
Published: 2021-08-05 (Crawled : 21:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 3.16%
H: 1.88%
C: 1.77%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.31%
H: 0.85%
C: 0.35%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.2%
H: 5.7%
C: 5.5%
treatment positive results trial topline
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Published: 2021-08-02 (Crawled : 22:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.44%
H: 0.89%
C: 0.88%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.43%
H: 0.88%
C: 0.35%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -1.81%
H: 0.94%
C: -0.19%
financial results results
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 0.49%
H: 0.26%
C: -0.62%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: -0.01%
H: 1.3%
C: -0.14%
new drug alcohol use disorder fda clearance treatment fda drug application clearance
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $123.9 -0.49% -0.47% 2.8M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | $750.77 -0.12% -0.23% 1.8M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | $147.7 -0.54% -0.49% 330K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
MDJH | $1.59 23.26% 19.88% 14K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.